Research programme: urological disorder therapeutics - IXALTIS

Drug Profile

Research programme: urological disorder therapeutics - IXALTIS

Alternative Names: IXA-002; IXA-003

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Developer IXALTIS
  • Class
  • Mechanism of Action Monoamine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Genitourinary disorders

Most Recent Events

  • 06 Jun 2016 Preclinical trials in Genitourinary disorders in France before June 2016 (IXALTIS pipeline, June 2016)
  • 06 Jun 2016 IXALTIS in-licenses IXA 002 and IXA 003 from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top